Clinical Trial Search

Primary: Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity…

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, After Each Vaccine Dose — 0; 0; 0; 8 Participants

Primary: Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3 — 17; 25 Episodes

Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants

Primary: C. Difficile Acquisition Rates — 13.2; 10.4 C. diff acquisition per patient days — p=0.611

Primary: Clostridium Difficile Infections Strain Type Based on Restriction Endonuclease Analysis — 3 cases of BI/NAP1/027

Primary: Clinical Remission Rates — 3; 2 Participants

Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days

Primary: Percentage of Participants With CDI Recurrence — 14.9; 15.7; 25.7 Percentage of participants — p=<0.0001

Primary: Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT). — 238…

Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants

Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants

Primary: Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14 — 2083.3; 3189.4; 32096.4 EU/mL — p=0.5746

Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants

Primary: Cure Rate at End of Therapy — 86.7; 87.7 Percentage of Participants